--- title: "Morning Trend | AKESO (9926.HK) Retraces to Support, Is a Rebound Window Coming?" type: "News" locale: "en" url: "https://longbridge.com/en/news/277749304.md" description: "As of the close on March 4th, the stock price continued to hover near the lower edge, with several attempts to test buying interest during the day but lacking sufficient strength, resulting in a weak rhythm. The funding situation appears more cautious, with not many proactive sell orders, but the buying support is also average, leading the market to choose to \"wait and see.\" In the short term, it remains below the key level, with frequent actions to test support, and while there was a momentary rebound in intraday trading, its sustainability was insufficient. Technically, the price is not far from the lower edge, which is commonly viewed as a phase for testing support. If there is a rapid rebound in the morning session, it could easily trigger emotional fluctuations. Right-side trading pays more attention to the continuity of signals, as a single upward movement is unlikely to change the weak tone. A unique observation is that last week, the overseas biomedical index experienced an overall pullback, and rising interest rate expectations led to valuation compression, which spilled over into the Hong Kong innovative drug sector. This external shock, combined with a local news vacuum, has caused funds within the sector to lean towards more stable cash flow varieties, amplifying the volatility of AKESO. On the market front, sub-sectors within pharmaceuticals that have stronger defensive attributes have shown relative resilience, while buying interest in innovative drug targets is more selective regarding price levels, showing a rhythm of \"low-point testing and upward probing.\" From a technical assistance perspective, the densely traded area at the near end still constitutes short-term pressure, and breaking above and stabilizing is usually interpreted by the market as a signal for rhythm switching. If the trading volume warms up in the morning session and the 5/10-day moving averages form a turning point and complete a price reversal, the quality of the rebound is expected to improve; conversely, if volume and price do not align, it may continue to hover near the lower edge, prolonging the bottoming process. It is important to be cautious that if there is another drop in the morning session that breaks through the support zone, the weakness may continue, and existing funds may further reduce risk exposure, shifting the trading focus downward" datetime: "2026-03-05T01:00:00.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/277749304.md) - [en](https://longbridge.com/en/news/277749304.md) - [zh-HK](https://longbridge.com/zh-HK/news/277749304.md) --- > Supported Languages: [简体中文](https://longbridge.com/zh-CN/news/277749304.md) | [繁體中文](https://longbridge.com/zh-HK/news/277749304.md) # Morning Trend | AKESO (9926.HK) Retraces to Support, Is a Rebound Window Coming? As of the close on March 4th, the stock price continued to hover near the lower edge, with several attempts to test buying interest during the day but lacking sufficient strength, resulting in a weak rhythm. The funding situation appears more cautious, with not many active sell orders, but the support is also average, leading the market to choose to "wait and see." In the short term, it remains below the key level, with frequent actions to test support, and while there was a momentary rebound in intraday trading, its sustainability was insufficient. Technically, the price is not far from the lower edge, which is commonly seen as a stage for testing support. If there is a rapid rebound in the morning session, it could easily trigger emotional fluctuations. Right-side trading is more concerned with signal continuity, and a single surge is unlikely to change the weak tone. The exclusive observation is that last week, the overseas biomedical index experienced an overall pullback, and rising interest rate expectations led to valuation compression, which spilled over into the Hong Kong innovative drug sector. This external shock, combined with a local news vacuum, has led funds within the sector to favor more stable cash flow varieties, amplifying the volatility of AKESO. On the market front, sub-sectors with stronger defensive attributes within pharmaceuticals have shown relative resilience, while buying interest in innovative drug targets has become more price-sensitive, exhibiting a rhythm of "low-point testing and upward probing." From a technical assistance perspective, the densely traded area at the near end still constitutes short-term pressure, and breaking above and stabilizing is usually interpreted by the market as a signal for rhythm switching. If the trading volume warms up in the morning session and the 5/10-day moving averages form a turning point and complete a price reversal, the quality of the rebound is expected to improve; conversely, if volume and price do not align, it may continue to hover near the lower edge, prolonging the bottoming process. It is important to be cautious that if there is another drop in the morning session that breaks through the support area, weakness may continue, and existing funds may further reduce risk exposure, shifting the trading focus downward. In terms of marginal variables, policy guidance, clinical milestones, and cooperation progress are expected to provide triggers; if positive catalysts appear along with incremental funds entering the market, a stable price with increased volume is more likely to occur. Overall, until a firm stabilization is confirmed, trading should primarily follow the trend, emphasizing the continuity of intraday support and the validation of not breaking during pullbacks ### Related Stocks - [Huaan Hang Seng Biotech ETF (159102.CN)](https://longbridge.com/en/quote/159102.CN.md) - [E Fund Hang Seng SCHK Innovative Drug ETF (159316.CN)](https://longbridge.com/en/quote/159316.CN.md) - [Tianhong CNI BIOMEDICINE ETF (159859.CN)](https://longbridge.com/en/quote/159859.CN.md) - [Yinhua CSI Innovative Drugs Industry ETF (159992.CN)](https://longbridge.com/en/quote/159992.CN.md) - [ChinaAMC Hang Seng Biotechnology Technology ETF(QDII) (159892.CN)](https://longbridge.com/en/quote/159892.CN.md) - [Bosera Hang Seng Health Care ETF(QDII) (513060.CN)](https://longbridge.com/en/quote/513060.CN.md) - [China Southern Hang Seng Biotech ETF(QDII) (159615.CN)](https://longbridge.com/en/quote/159615.CN.md) - [Bosera Hang Seng SCHK Innovative Drug Select ETF (520690.CN)](https://longbridge.com/en/quote/520690.CN.md) - [AKESO (09926.HK)](https://longbridge.com/en/quote/09926.HK.md) - [GF CSI HK Innovative Drugs Industry ETF(QDII) (513120.CN)](https://longbridge.com/en/quote/513120.CN.md) - [Hwabao WP Hang Seng SCHK Innovative Drug Select ETF (520880.CN)](https://longbridge.com/en/quote/520880.CN.md) - [Fullgoal Hang Seng SCHK Innovative Drug & Healthcare ETF (159506.CN)](https://longbridge.com/en/quote/159506.CN.md) ## Related News & Research - [CICC Remains a Buy on Akeso, Inc. (9926)](https://longbridge.com/en/news/281674709.md) - [10:00 ETSanyou Milestone | Recognized as a "Shanghai Municipal Enterprise Technology Center," Further Validating for Innovation Excellence](https://longbridge.com/en/news/281035304.md) - [Junshi Biosciences Chairman Completes RMB100 Million Shareholding Increase](https://longbridge.com/en/news/281231901.md) - [3SBio Nearly Doubles Revenue and Quadruples Profit in 2025, Keeps Dividend Steady](https://longbridge.com/en/news/281054154.md) - [ImmuneOnco Doses First Patient in Phase III Trial of CD47/CD20 Bispecific for Lymphoma](https://longbridge.com/en/news/281068292.md)